NCT03421054CompletedNot Applicable
Pilot, Open Non-controled Trial to Assess the Feasibility of Implementing Objective Parameters as Primary Endpoints in a Clinical Trial With Patients Affected by Knee Osteoarthritis
River Pharma S.r.l.1 site in 1 country8 target enrollmentStarted: March 19, 2018Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- synovial effusion reduction
Study Overview
Brief Summary
Pilot, open non-controlled trial to assess the feasibility of implementing objective parameters as primary endpoints in a clinical trial with patients affected by knee osteoarthritis.
Detailed Description
• to assess the feasibility of implementing ultrasonography and Range of motion (ROM) as objective measurements to correlate the improvement of the knee mobility with the pain reduction of the affected knee in the patients assuming nutraceutical containing HA.
The secondary objectives of the trial are:
- to assess the feasibility of implementing Actigraphy as objective measurements to correlate the improvement of the knee mobility with the pain reduction (optional).
- to evaluate the enrollment range in one month.
The explorative objectives of the trial are:
• Preliminary data on efficacy of the tested product
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 50 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Any gender and age from 50 to 70 years
- •Symptomatic osteoarthritis (OA) of the knee with mild joint discomfort for at least 6 months prior to enrollment, following ACR criteria with history and physical examination (1). Subjects diagnosed with bilateral knee OA will be asked to specify the most affected knee at baseline, and this knee will be evaluated throughout the study period.
- •Available confirmatory X-ray (performed within the previous 6 months) diagnosis (Kellgren/Lawrence score 2) at the evaluated knee joint (2).
- •Subjects experienced pain for at least 15 of the 30 days prior to the start of the study.
Exclusion Criteria
- •Subjects who have any inflammatory arthritic condition (different from the OA of the knee), fibromyalgia, multiple sclerosis or autoimmune disorder.
- •Treatment with oral corticosteroids within 4 weeks before screening.
- •Intra-articular injections of HA or corticosteroids in the target joint within 3 months before screening.
- •Treatment with anti-inflammatory or chondroprotective drugs (chondroitin sulfate, glucosamine, methylsulfonylmethane, HA, diacerein) 2 weeks before the selection.
- •HA-containing nutritional supplements or cosmetics during the month before the study.
- •Previous surgical treatment of knee joint(s) or its necessity; complication(s) necessary for hospitalization and surgical treatment.
- •Significant injury to the target joint within the past 6 months prior to screening (identified from medical history).
- •Subjects following an energy-restricted diet for weight loss.
- •Pregnant women, nursing mothers, or women (only if childbearing potential) not using adequate methods of contraception.
- •Subjects with cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study.
- •Participation in an interventional clinical study in the previous 30 days.
- •Presence of any clinically significant medical condition judged by the investigator to preclude the patient's inclusion in the study.
Arms & Interventions
nutraceutical containing HA
Other
pain reduction of the affected knee in the patients assuming nutraceutical containing HA
Intervention: patients assuming nutraceutical containing HA (Dietary Supplement)
Outcomes
Primary Outcomes
synovial effusion reduction
Time Frame: week 4 and 8
Correlation between reduction in VAS (at rest) and ultrasonography parameters
Secondary Outcomes
- pain reduction(week 4 and 8)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Phase 1
Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) SurgeryEpilepsyNCT06280092Mayo Clinic1
Completed
Phase 1
Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas AeruginosaVentilator Associated PneumoniaPneumoniaNCT00851435Kenta Biotech Ltd15
Recruiting
Not Applicable
Examining the efficacy of a sleep-wake management tool for shift workersshift work disordersleep disorderdepressionstressanxietypoor cognitive performanceMental Health - Studies of normal psychology, cognitive function and behaviourinsomniaACTRN12622000836730Defence, Science and Technology Group (DSTG)40
Completed
Phase 3
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)Myasthenia GravisNCT02774239University of Alberta26
Completed
Not Applicable
A Pilot Study of patients with Oligometastases from Prostate cancer treated with Stereotactic Ablative Body RadiosurgeryMetastatic Prostate Cancer (oligometastatic 1-3 metastases)Cancer - ProstateACTRN12613000436774Peter MacCallum Cancer Centre30